Researchers say a urine screening may be accurate at identifying human papillomavirus (HPV).
Cisplatin plus pemetrexed improved response rates and survival rates of patients with advanced cervical cancer.
A clinical trial is underway that may provide women with a more accurate way to detect cervical cancer.
The FDA has approved a new use against late-stage cervical cancer.
A long-term follow-up study shows the sustained efficacy, immunogenicity, and safety of GlaxoSmithKline's human papillomavirus (HPV) vaccine Cervarix. Women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine were followed for more than 9 years, and vaccine efficacy (VE) against incident infection was 100%.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|